DKDeniz Eyice Karabacak

Deniz Eyice Karabacak

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Deniz Eyice Karabacak has a total of 134 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • The Sting Challenge Test: An EAACI Position Paper on Hymenoptera Venom Allergy

    by Arantza Vega Castro, Christine Breynaert, Teresa Alfaya, Maria Beatrice Bilò, Filippo Fassio, Deniz Eyice Karabacak, Matteo Martini, Ümit Murat Sahiner, Berta Ruiz‐León, Kymble Spriggs, et al.

    A Sting Challenge Test (SCT) is the only reliable method to verify the effectiveness of venom immunotherapy (VIT) in patients allergic to Hymenoptera venom, a leading cause of anaphylaxis in adults. This European Academy of Allergy and Clinical Immunology (EAACI) position paper provides an in‐depth analysis of the SCT's key applications, risks, and outcomes in clinical practice, focusing on its role in monitoring VIT efficacy, improving patient quality of life, and ensuring appropriate therapeutic interventions. The SCT is primarily used to assess VIT protection, adjust VIT dosage, and confirm patient safety but is not recommended for routine diagnosis due to the risk of provoking systemic allergic reactions. This position paper also offers practical considerations for performing the SCT, including insect handling, patient preparation, and risk management. While SCT is a valuable tool in personalized allergy treatment, it requires careful handling of live insects and patient preparation to ensure safety. This position paper reviews the literature and presents the expert experience of the Insect Venom Hypersensitivity Working Group of the European Academy of Allergy and Clinical Immunology.


  • Open Access

    C1 inhibitor deficient hereditary angioedema is related to endothelial dysfunction in young adult and middle‐aged patients

    by Gokce Gul Atay Sensoy, Derya Baykız, İlKim Deniz Toprak, Deniz Eyice Karabacak, Erdem Bektas, Derya Unal, Aslı Gelincik, Semra Demir

    Background: Hereditary angioedema (HAE) is a rare, autosomal dominantly inherited disease characterised by mucocutaneous oedema attacks. Vasoactive mediators and the endothelium play an important role in the pathogenesis of HAE. We aimed to evaluate the endothelial dysfunction in HAE.Methods: The study included 35 C1 inhibitor deficient (C1‐INH) HAE patients aged 18–50 years old without any risk factor that could cause endothelial dysfunction, and 25 sex‐ and age‐matched healthy controls (HCs). Bilateral carotid intima‐media thickness (CIMT), flow‐mediated dilation (FMD) measurements, and transthoracic echocardiography (ECHO) imaging were performed. Demographic and clinical features of the patients were evaluated.Results: The percentage of FMD (FMD [%]) in C1‐INH HAE patients was significantly lower than in the HCs (p < 0.001). There was no significant difference in the CIMT between C1‐INH HAE patients and HCs. In addition, the findings of the ECHO were similar between the groups. C4 and C1 INH levels at diagnosis, gender, age, disease severity, presence of long‐term prophylaxis treatment and attack frequency were not associated with FMD (%), whereas disease duration was correlated with lower FMD (%) (r = −0.480, p = 0.003).Conclusion: The present study indicated the presence of structural endothelial dysfunction in C1‐INH HAE in the absence of atherosclerosis. Moreover, the study revealed that endothelial dysfunction was associated with disease duration, irrespective of disease severity. Further studies are required in order to assess mortality and morbidity due to endothelial dysfunction in C1‐INH HAE and to determine the molecular mechanisms underlying endothelial dysfunction in C1‐INH HAE.


  • Open Access

    Soybean Oil in Propofol Is Not Able to Induce Allergic Reactions

    by Deniz Eyice Karabacak, Lisa Arzt‐Gradwohl, Barbara Binder, Eva Schadelbauer, Christina Vallant, Karin Laipold, Gunter J. Sturm


  • Obituary: Professor Peter Valentin Tomazic, Graz, Austria

    by Ludger Klimek, Adam Chaker, Valérie Hox, Stefano Del Giacco, Philippe Gevaert, Mohamed Shamji, Sanna Toppila Salmi, Patrizia Bonadonna, Jolanta Walusiak‐Skorupa, André Morreira, et al.

  • Reply to corresponcence: “Oral immunotherapy in alpha‐gal red meat allergy: Could specific IgE be a potential biomarker in monitoring management?”

    by D. Ünal, D. Eyice‐Karabacak, A. Kutlu, S. Demir, O. C. Tüzer, F. A. Arslan, S. R. Işık, A. Gelincik

  • Open Access

    Validity and reliability of Turkish version of quality-of-life questionnaire in adult patients with common variable immune deficiency

    by Deniz Eyice, Semra Demir, Halim İşsever, Osman Ozan Yeğit, Ali Can, Özdemir Can Tüzer, Pelin Karadağ, Nida Öztop, Şengül Beyaz, Bahauddin Çolakoğlu, et al.

    Background and Aims Common variable immunodeficiency (CVID) can affect quality of life (QoL) which can be better assessed with validated scales. Our goal was to validate the Turkish version of the Italian CVID-QoL questionnaire. Methods International recommendations for cultural adaptation and translation process of original scale was followed. CVID patients completed Turkish CVID-QoL questionnaire between October 2019 and January 2020. The Short Form Health Survey (SF-36) was used as a comparative questionnaire. Reliability, reproducibility, factor analysis, content validity, convergent validity and discriminant validity were analysed. Results 50 CVID patients were included in the study. 64 % of patients (n=32), the mean age of the patients was 36.68 ± 13.2 years, the median duration of disease was 52.5 months. The instrument had good internal consistency in 50 patients [Cronbach’s alpha: 0.92, emotional functioning (EF): 0.91, relational functioning (RF): 0.77]. It also revealed high reproducibility in 26 patients QoL global, intraclass correlation coefficient (ICC)= 0.80 (95 % CI 0.56 - 0.91); EF, ICC = 0.78 (95 % CI 0.51- 0.90); RF, ICC = 0.82 (95 % CI 0.59-0.92); Gastrointestinal and skin symptoms (GSS), ICC = 0.89 (95 % CI 0.76-0.95); (p <0.001, p <0.001, p <0.001, p <0.001). QoL global, EF and RF scores showed good convergent validity with similar subscales of SF-36. The number of infections within last 3 months had a significant impact on QoL global, EF and RF (p=0.038, p=0.045, p=0.028). Conclusions The Turkish version of CVID QoL scale has appropriate validity and reliability among Turkish patients with CVID.

  • Mentoring as the cornerstone of continued education in Allergy and Clinical Immunology: 10th anniversary of the EAACI mentorship program

    by Mattia Giovannini, Burcin Beken, Ioana Agache, Cezmi A. Akdis, Daniela Carvalho, Tomas Chivato, Pasquale Comberiati, Leticia De Las Vecillas, Ibon Eguiluz‐Gracia, Enrico Heffler, et al.


  • Oral immunotherapy in alpha‐gal red meat allergy: Could specific IgE be a potential biomarker in monitoring management?

    by D. Ünal, D. Eyice‐Karabacak, A. Kutlu, S. Demir, C. Tüzer, A. F. Arslan, S. R. Işık, A. Gelincik

    Background: Oral immunotherapy (OIT) is a promising treatment for food allergies. Our aim was to establish the long‐term safety and efficacy of a novel red meat (RM) OIT in galactose‐alpha‐1,3‐galactose (alpha‐gal) allergy in adults.Methods: Out of 20 patients with confirmed RM allergy, five (41.66%) underwent an early OIT, seven (58.33%) underwent a delayed protocol and eight patients who were not desensitized formed the patient control group. 15 and 27 day RM OIT for early‐onset and delayed‐onset alpha‐gal allergy were administered, respectively. Desensitized patients were recommended to continue eating at least 100 g RM every day for 6 months and every other day in the following 6 months. After a year, the consumption was recommended 2/3 times in a week. Patients were followed up with skin tests with commercial beef and lamb extracts, fresh raw/cooked beef and lamb and cetuximab and also with serum alpha‐gal specific Immunoglobulin‐E (sIgE) in the first and fifth years.Results: All patients who underwent OIT became tolerant to RM. During the 5 year follow‐up, the median alpha‐gal sIgE concentration gradually decreased in nine patients who consumed RM uneventfully while remained unchanged in the control group (p = .016). In two patients, rare tick bites acted as inducers of hypersensitivity reactions with concomitant elevation of alpha‐gal sIgE concentrations whereas one patient with low follow‐up alpha‐gal sIgE concentrations consumed RM uneventfully after frequent tick bites.Conclusions: Our study showed the long‐term safety and efficacy of alpha‐gal OIT. Additionally, alpha‐gal sIgE seems to be a potential biomarker to monitor OIT.